New drugs show promise in treating deadly melanoma

PLX4032, or vemurafenib, is the first chemotherapy agent directed at a specific mutation involved in the formation of skin tumors, which occurs in about half of <a class="taxInlineTagLink" id="HEDAI0000038" title="Skin Cancer" href="/topic/health/diseases-illnesses/skin-cancer-HEDAI0000038.topic">melanoma</a> patients. Ipilimumab, marketed as Yervoy, stimulates the immune system to fight tumors, and has proven to be more effective than both conventional chemotherapy and a vaccine used to treat melanoma. Researchers reported the findings on June 5 at a meeting of the American Society of Clinical Oncology.
hk-skin-cancer-drugs-photo

( Business Wire )

PLX4032, or vemurafenib, is the first chemotherapy agent directed at a specific mutation involved in the formation of skin tumors, which occurs in about half of melanoma patients. Ipilimumab, marketed as Yervoy, stimulates the immune system to fight tumors, and has proven to be more effective than both conventional chemotherapy and a vaccine used to treat melanoma. Researchers reported the findings on June 5 at a meeting of the American Society of Clinical Oncology.

  • Email E-mail
  • add to Twitter Twitter
  • add to Facebook Facebook
  • Home Delivery Home Delivery

PHOTO GALLERIES

TOP VIDEO

CONNECT WITH US


2013 YEAR IN REVIEW
Look for this special section in your
Baltimore Sun newspaper on Dec. 29, 2013.
  • Twitter
  • Facebook
  • Instagram
  • Google Plus
  • RSS Feeds
  • Mobile Alerts and Apps

Contact Us | Newsroom directory | Social Sun